Antimicrobial Use in Pediatric Oncology and Hematology: Protocol for a Multicenter Point-Prevalence Study With Qualitative Expert Panel Assessment.
antimicrobial resistance
antimicrobial stewardship
cancer
expert panel
oncology
pediatric hematology
pediatric oncology
pediatrics
point-prevalence study
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
20 Jun 2022
20 Jun 2022
Historique:
received:
17
12
2021
accepted:
22
04
2022
revised:
07
04
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
21
6
2022
Statut:
epublish
Résumé
Because infections are a major driver of morbidity and mortality in children with hematologic or oncologic diseases, antimicrobials are frequently prescribed in pediatric oncology practice. However, excess or inappropriate use of antimicrobials is directly linked to the emergence of antimicrobial resistance. Although point-prevalence studies have examined the extent of antimicrobial use, a comprehensive qualitative evaluation of individual antimicrobial prescriptions remains lacking. The aim of this study is to identify appropriate versus inappropriate antimicrobial use among pediatric cancer patients in a point-prevalence study, followed by an expert panel adjudication process and a subsequent report of these findings to participating centers. This study also aims to improve the quality of patient care by informing centers about discrepancies between internal standards of care and national guidelines. Our point-prevalence study is performed at pediatric cancer centers in Germany and Austria. All patients under 18 years old who are hospitalized at the time of the study are included. As a supplement to the point-prevalence study, an expert panel is qualitatively assessing each of the antimicrobial prescriptions at the participating centers to review local guidelines and compare them with national guidelines. As of December 2021, the point-prevalence survey has been conducted at 30 sites and expert panel adjudication for qualitative assessment of each antimicrobial use is ongoing. Results of the study are expected in 2022. This is the first point-prevalence study conducted among pediatric cancer centers with an integrated, multistep, qualitative approach that assesses each antimicrobial prescription. The results of this study will inform possible interventions for internal guidelines and antimicrobial stewardship programs implemented at pediatric cancer centers. In addition, local guidelines will be compared with national guidelines. Furthermore, this study will contribute to the overall integration of antimicrobial stewardship principles and initiatives in pediatric oncology and hematology, thereby improving safety and quality of care for children and adolescents with cancer and blood disorders. DERR1-10.2196/35774.
Sections du résumé
BACKGROUND
BACKGROUND
Because infections are a major driver of morbidity and mortality in children with hematologic or oncologic diseases, antimicrobials are frequently prescribed in pediatric oncology practice. However, excess or inappropriate use of antimicrobials is directly linked to the emergence of antimicrobial resistance. Although point-prevalence studies have examined the extent of antimicrobial use, a comprehensive qualitative evaluation of individual antimicrobial prescriptions remains lacking.
OBJECTIVE
OBJECTIVE
The aim of this study is to identify appropriate versus inappropriate antimicrobial use among pediatric cancer patients in a point-prevalence study, followed by an expert panel adjudication process and a subsequent report of these findings to participating centers. This study also aims to improve the quality of patient care by informing centers about discrepancies between internal standards of care and national guidelines.
METHODS
METHODS
Our point-prevalence study is performed at pediatric cancer centers in Germany and Austria. All patients under 18 years old who are hospitalized at the time of the study are included. As a supplement to the point-prevalence study, an expert panel is qualitatively assessing each of the antimicrobial prescriptions at the participating centers to review local guidelines and compare them with national guidelines.
RESULTS
RESULTS
As of December 2021, the point-prevalence survey has been conducted at 30 sites and expert panel adjudication for qualitative assessment of each antimicrobial use is ongoing. Results of the study are expected in 2022.
CONCLUSIONS
CONCLUSIONS
This is the first point-prevalence study conducted among pediatric cancer centers with an integrated, multistep, qualitative approach that assesses each antimicrobial prescription. The results of this study will inform possible interventions for internal guidelines and antimicrobial stewardship programs implemented at pediatric cancer centers. In addition, local guidelines will be compared with national guidelines. Furthermore, this study will contribute to the overall integration of antimicrobial stewardship principles and initiatives in pediatric oncology and hematology, thereby improving safety and quality of care for children and adolescents with cancer and blood disorders.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/35774.
Identifiants
pubmed: 35723906
pii: v11i6e35774
doi: 10.2196/35774
pmc: PMC9253971
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e35774Informations de copyright
©Cihan Papan, Katharina Reifenrath, Katharina Last, Andishe Attarbaschi, Norbert Graf, Andreas H Groll, Johannes Huebner, Hans-Jürgen Laws, Thomas Lehrnbecher, Johannes Liese, Luise Martin, Tobias Tenenbaum, Stefan Weichert, Simon Vieth, Ulrich von Both, Markus Hufnagel, Arne Simon. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 20.06.2022.
Références
J Antimicrob Chemother. 2016 Apr;71(4):1106-17
pubmed: 26747104
Front Public Health. 2020 Jul 17;8:293
pubmed: 32766196
Infect Drug Resist. 2021 Mar 30;14:1283-1293
pubmed: 33833534
Monatsschr Kinderheilkd. 2021;169(5):443-450
pubmed: 33746294
Infect Dis Clin North Am. 2014 Jun;28(2):263-79
pubmed: 24857392
Clin Microbiol Infect. 2022 May;28(5):723-730
pubmed: 34768022
Clin Infect Dis. 2020 Jun 24;71(1):226-236
pubmed: 31676904
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Curr Opin Pediatr. 2019 Feb;31(1):35-40
pubmed: 30461508
J Clin Epidemiol. 2019 Aug;112:20-27
pubmed: 30930247
Lancet. 2019 Jan 12;393(10167):183-198
pubmed: 30558872
Pediatr Infect Dis J. 2015 Jul;34(7):734-41
pubmed: 25607829
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Oct;55(10):1311-54
pubmed: 23011096
Lancet Oncol. 2021 Jun;22(6):e270-e280
pubmed: 33811814
BMC Infect Dis. 2020 Aug 17;20(1):606
pubmed: 32807104
BMJ Open. 2016 Nov 3;6(11):e012675
pubmed: 27810974
Klin Padiatr. 2021 May;233(3):123-126
pubmed: 33601432
Infection. 2020 Aug;48(4):607-618
pubmed: 32524514
Leuk Lymphoma. 2013 Aug;54(8):1633-9
pubmed: 23163631
Pediatr Infect Dis J. 2013 Jun;32(6):e242-53
pubmed: 23838740